COMPASS Pathways was granted U.S. Patent No. 10,519,175 which covers COMP360, their investigational psilocybin formulation which developed and produced by COMPASS Pathways. The patent covers methods of treating drug-resistant depression by administering particular dosage forms. Those dosage forms include explicit requirements that are based on interpreting x-ray diffraction data.
COMPASS Pathways Awarded Patent for Psilocybin Formulation COMP360
The scope and validity of the patent will depend on how x-ray diffraction data is interpreted.